Development
Silo Pharma, Inc.
SILO
$0.6293
$0.0315.18%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 4.34% | 146.99% | 100.49% | 89.56% | 34.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.18% | 121.16% | 71.29% | 63.35% | 88.91% |
| Operating Income | 18.52% | -125.57% | -74.11% | -64.48% | -92.18% |
| Income Before Tax | 32.85% | -53.86% | -50.34% | -57.31% | -115.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.85% | -53.86% | -50.34% | -56.45% | -115.19% |
| Earnings from Discontinued Operations | -- | -- | -- | 100.00% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.85% | -53.86% | -50.04% | -52.73% | -115.40% |
| EBIT | 18.52% | -125.57% | -74.11% | -64.48% | -92.18% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 56.79% | 3.02% | 6.30% | 5.06% | -115.19% |
| Normalized Basic EPS | 55.33% | -28.44% | -0.34% | 1.91% | -89.14% |
| EPS Diluted | 56.79% | 3.02% | 6.30% | 5.06% | -115.35% |
| Normalized Diluted EPS | 55.33% | -28.44% | -0.34% | 1.91% | -91.10% |
| Average Basic Shares Outstanding | 55.39% | 58.65% | 60.13% | 60.90% | 1.42% |
| Average Diluted Shares Outstanding | 55.39% | 58.65% | 60.13% | 60.90% | 0.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |